about
Expressed sequence tag profiling identifies developmental and anatomic partitioning of gene expression in the mouse prostateAndrogen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.Tumor characterization with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.Vitamin D metabolism and action in the prostate: implications for health and disease.miR 488* inhibits androgen receptor expression in prostate carcinoma cellsGrowth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.Pre-clinical mouse models of human prostate cancer and their utility in drug discoveryDissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol.Advances in mouse models of prostate cancer.Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.The role of murine models of prostate cancer in drug target discovery and validation.Current mouse and cell models in prostate cancer research.Reciprocal Control of Thyroid Binding and the Pipecolate Pathway in the Brain.Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells.Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer.Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells.Evaluation of the antiproliferative effects of Essiac on in vitro and in vivo models of prostate cancer compared to paclitaxel.TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.
P2860
Q24793732-CC283BE8-511A-48D8-8218-286082A83221Q30482634-7CF4AEF8-A55C-4624-B49F-5CE1963A126EQ33584677-82F1580C-1A35-4A93-A912-9B103A68FE7EQ33696276-185C1BB2-9E21-43E6-A1B0-C6349FB41AA6Q34027269-04B62752-3B51-4553-AF2A-602E9825250BQ34196086-A8B60CA0-4739-4323-B5AE-53CD19DC71BFQ34330174-E190CA36-60A3-4BFC-ADCC-6518B494A76DQ34771567-82A9F21F-E510-4A85-ACC6-193D2D4F36F2Q36357373-DE088AA7-4654-4421-AE04-41D25036BA85Q37084443-F68F5DAD-A988-4FB5-A62B-D655F801445BQ37185527-3B675A6D-042C-41F1-B9D7-32A41D4B6720Q37352625-641E81F8-E4CE-4B88-915D-8F533C47EB21Q38089910-97AE322D-993F-494C-9246-395D7D8E9353Q38098499-FF1BFD53-B827-4EA6-810F-1039C8423A2CQ38925886-2F4CED00-4B2A-490C-86A1-8908EA05FDCDQ42014039-E21927AD-CAE2-492D-A5CA-7AE61B0306FDQ42252090-6D378B81-0374-44FA-BA98-21CDE1068492Q42353164-93F07B46-12FE-4090-9638-330ECED63CC8Q42574095-E33BE21E-616F-4AD2-8615-8434FC7C6272Q47784970-67BD1256-6DB6-42F7-BE15-CD42211E04FDQ53539808-A03AA12F-6D85-4105-A9CD-0ACF96E27B6CQ54403866-686F0543-834D-435C-82AE-425A17570E2E
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Model systems of prostate cancer: uses and limitations.
@ast
Model systems of prostate cancer: uses and limitations.
@en
type
label
Model systems of prostate cancer: uses and limitations.
@ast
Model systems of prostate cancer: uses and limitations.
@en
prefLabel
Model systems of prostate cancer: uses and limitations.
@ast
Model systems of prostate cancer: uses and limitations.
@en
P2093
P356
P1476
Model systems of prostate cancer: uses and limitations.
@en
P2093
Logothetis CJ
Troncoso P
von Eschenbach AC
P2888
P304
P356
10.1023/A:1006165017279
P577
1998-01-01T00:00:00Z
P6179
1007739387